ストックスクリーナーアプリを入手
6.95
4.79%
-0.35
Kazia Therapeutics Limited Adr (KZIA) 最新ニュース
Kazia Therapeutics (NASDAQ: KZIA) registers 10.7M ADSs, reports $69.46M cash - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) registers 266,666 ADSs; posts half‑year update - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) files prospectus supplement for 232,956 ADSs - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) director Coffey details ADS options and share stakes - Stock Titan
Kazia Therapeutics (KZIA) CEO discloses multi-million share option stakes on Form 3 - Stock Titan
Kazia Therapeutics (KZIA) VP discloses initial ADS option grants - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) files $200M shelf; $100M ATM with Leerink - Stock Titan
Maxim Group Sticks to Its Buy Rating for Quoin Pharmaceuticals (QNRX) - The Globe and Mail
Jorey Chernett holds 12.46% of Kazia Therapeutics (KZIA) ADS - Stock Titan
Ikarian Capital discloses 5.1% Kazia Therapeutics (KZIA) ADS position - Stock Titan
Dauntless Investment trims Kazia Therapeutics (KZIA) position to negligible 0.0% - Stock Titan
Kazia Therapeutics stock rises on promising nuclear PD-L1 degrader data By Investing.com - Investing.com India
Kazia Therapeutics stock rises on promising nuclear PD-L1 degrader data - Investing.com UK
Experimental cancer drug targets hidden resistance driving metastasis - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) posts early TNBC trial gains in paxalisib study - Stock Titan
Early paxalisib TNBC responses highlighted by Kazia Therapeutics (NASDAQ: KZIA) - Stock Titan
Early paxalisib TNBC data: Kazia Therapeutics (NASDAQ: KZIA) sees partial and complete responses - Stock Titan
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End - Benzinga
United States shares mixed at close of trade; Dow Jones Industrial Average up 0.66% _newTouch_By Investing.com - Investing.com India
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.66% - Investing.com
Kazia Therapeutics (KZIA) resale filing details $46.5M cash boost and runway to 2028 - Stock Titan
Kazia Therapeutics Retains Nasdaq Listing After Regaining Compliance - The Globe and Mail
Kazia Therapeutics secures $46.5 million through private placement to address Nasdaq compliance - MSN
Kazia Therapeutics Secures $46.5 Million Through Private Placement to Address Nasdaq Compliance - The Globe and Mail
You might want to take a look at Kazia Therapeutics Limited ADR (KZIA) now - setenews.com
Kazia Therapeutics (NASDAQ: KZIA) expects $46.5M net from PIPE to extend cash runway - Stock Titan
Check out these key findings about Hub Cyber Security Ltd (HUBC) - setenews.com
What is Kazia Therapeutics Limited ADR (KZIA) Stock Return on Shareholders’ Capital? - Setenews
Kazia Therapeutics Limited (KZIA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Kazia Therapeutics reports immune complete response in TNBC - MSN
KZIA Shares Surge: Can This Momentum Last? - StocksToTrade
Kazia Therapeutics (KZIA) Stock Soars on Breakthrough Results in Breast Cancer Treatment - parameter.io
Kazia Therapeutics receives Nasdaq delisting notice, plans to request hearing By Investing.com - Investing.com India
Kazia Therapeutics receives Nasdaq delisting notice, plans to request hearing - Investing.com
Kazia Therapeutics Achieves Initial iCR… - digitalmore.co
Kazia reports immune-complete response in metastatic breast cancer By Investing.com - Investing.com South Africa
Kazia reports immune-complete response in metastatic breast cancer - Investing.com
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy - The Manila Times
Kazia stock soars after patient shows complete response in TNBC trial - Investing.com Nigeria
[424B3] KAZIA THERAPEUTICS LTD Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
Kazia (Nasdaq: KZIA) reports iCR in metastatic TNBC and outlines Q4 oncology pipeline - Stock Titan
[6-K] KAZIA THERAPEUTICS LTD Current Report (Foreign Issuer) | KZIA SEC FilingForm 6-K - Stock Titan
[20-F] KAZIA THERAPEUTICS LTD Files Annual Report (Foreign Issuer) | KZIA SEC FilingForm 20-F - Stock Titan
How Does Wall Street Rate Shares Of DoubleDown Interactive Co Ltd ADR (DDI)? - fostersleader.com
Is Buying Stock In MediWound Ltd (MDWD) A Good Move Today? - fostersleader.com
Kazia Therapeutics stock seeks FDA guidance on paxalisib approval path - Investing.com
Kazia (NASDAQ: KZIA) to request FDA Type C on GBM OS; NDA path under review - Stock Titan
A Look at HighPeak Energy Inc (HPK) Shares in the Recent Past Indicates Growth - Setenews
Kazia (KZIA) secures PD-L1 degrader NDL2 with $1.39M payment - Stock Titan
Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program - Stock Titan
0.99%
3.03%
大文字化:
|
ボリューム (24 時間):